Tryp Therapeutics Explores Psilocybin's Potential In New Trials To Treat IBS And Fibromyalgia
Tryp Therapeutics Explores Psilocybin's Potential In New Trials To Treat IBS And Fibromyalgia
Tryp Therapeutics在治疗肠易激综合征和纤维肌痛的新试验中探索迷幻药的潜力
Psychedelics biotech Tryp Therapeutics (OTCQB:TRYPF) is advancing its psilocybin-based portfolio through several recent milestones.
迷幻药生物技术公司Tryp Therapeutics（OTCQB: TRYPF）正在通过最近的几个里程碑推进其基于迷幻药的产品组合。
Upcoming Phase 1 For IV Psilocin
IV Psilocin即将推出的第一阶段
First, the company received approval from the Australian Human Research Ethics Committee (HREC) for a Phase 1 study on its IV-infused psilocin, TRP-8803. To take place at the CMAX Phase 1 unit in Adelaide, Australia, the open-label study will assess the safety and pharmacokinetics (PK) of a single intravenous (IV) infusion of the psychedelic in nine healthy adults.
首先，该公司获得了澳大利亚人类研究伦理委员会（HREC）的批准，可以对其注入静脉注射的迷幻药 TRP-8803 进行第一期研究。这项开放标签研究将在澳大利亚阿德莱德的CMAX第一期研究室进行，将评估九名健康成年人单次静脉注射（IV）迷幻药的安全性和药代动力学（PK）。
On a broader scale, the trial is designed to determine the optimal blood levels of psilocin to achieve the targeted psychedelic...
在更广泛的范围内，该试验旨在确定psilo...
登录免费看全文
登录/注册